<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0"><channel><title>Individual feed for https://www.medscape.com/cx/rssfeeds/2700.xml</title><link>https://www.medscape.com/cx/rssfeeds/2700.xml</link><description>Individual feed output.</description><lastBuildDate>Sun, 08 Jun 2025 02:36:16 GMT</lastBuildDate><generator>PyRSS2Gen-1.1.0</generator><docs>http://blogs.law.harvard.edu/tech/rss</docs><item><title>Pegcetacoplan Maintains Kidney Benefits at 52 Weeks</title><link>https://www.medscape.com/viewarticle/pegcetacoplan-maintains-kidney-benefits-52-weeks-2025a1000fd7?src=rss</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture6.png</image_url><description>Significant reductions in proteinuria, estimated glomerular filtration rate stability of the C3/C3b inhibitor were also observed in key subgroups, inc...</description><pubDate>Sun, 08 Jun 2025 01:40:36 GMT</pubDate></item><item><title>Limited Survival Benefit With Expanded Kidney Donor Criteria</title><link>https://www.medscape.com/viewarticle/limited-survival-benefit-expanded-kidney-donor-criteria-2025a1000fd5?src=rss</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture6.png</image_url><description>The universal survival benefit with kidney transplant over dialysis does not apply to older and high-risk patients receiving an expanded criteria orga...</description><pubDate>Sat, 07 Jun 2025 18:58:37 GMT</pubDate></item><item><title>Sibeprenlimab Halves uPCR in IgA Nephropathy Trial</title><link>https://www.medscape.com/viewarticle/sibeprenlimab-halves-upcr-iga-nephropathy-trial-2025a1000fcm?src=rss</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture9.png</image_url><description>The novel selective antibody sibeprenlimab reduced proteinuria more than any prior drug for IgA nephropathy, with excellent safety outcomes, interim p...</description><pubDate>Fri, 06 Jun 2025 19:43:07 GMT</pubDate></item><item><title>Nefecon Shows IgAN Benefits Regardless of Baseline eGFR</title><link>https://www.medscape.com/viewarticle/nefecon-shows-igan-benefits-regardless-baseline-egfr-2025a1000fcd?src=rss</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture5.png</image_url><description>A subanalysis of the NeflgArd study shows benefits in eGFR and urine protein-creatinine ratio at baseline and across timepoints, regardless of baselin...</description><pubDate>Fri, 06 Jun 2025 19:08:11 GMT</pubDate></item><item><title>Canagliflozin CV Benefits Appear to Be Dose-Dependent</title><link>https://www.medscape.com/viewarticle/canagliflozin-cv-benefits-appear-be-dose-dependent-2025a1000fby?src=rss</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture3.png</image_url><description>A post-hoc analysis of the pivotal CANVAS trial shows those receiving higher dose canagliflozin are more likely to experience the cardiovascular benef...</description><pubDate>Fri, 06 Jun 2025 18:00:40 GMT</pubDate></item></channel></rss>